CARDIAC Publication-derived

CM (iPSC)

Source Burridge et al. · Stanford Cardiovascular Institute, Stanford University, Stanford, USA · 10.1038/nm.4087

👤 Burridge PW, Li YF, Matsa E, Wu H, Ong SG, Sharma A, Holber A, Diecke S, Wu JC ⏱ 10080 min 🧫 iPSC-Derived (Patient-Specific iPSCs — Breast Cancer Patients)

Abstract

Burridge et al. demonstrated that iPSC-CMs from breast cancer patients who developed clinical doxorubicin cardiotoxicity were more sensitive to doxorubicin in vitro than those from resilient patients. This personalized approach enables individual risk stratification and identified genetic variants associated with anthracycline susceptibility.

Cell source

iPSC-Derived (Patient-Specific iPSCs — Breast Cancer Patients)

Application

Anthracycline Cardiotoxicity Prediction

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Burridge et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence